rivaroxaban. Rivaroxaban patent expiration date as a result of the extension for more than 3.7 years and updated the patent information for Xarelto in.
8. Bayer’s Xarelto. Patent expiration: August 2025. Xarelto (rivaroxaban), a Factor Xa inhibitor approved in 2025, is widely prescribed for preventing and treating blood clots
patent expiration. The NMPA conducts examination by Rivaroxaban (Xarelto), Bayer's compound patent has never before been challenged.
At the same time, the Bayer drug is protected by a patent, which expires in December 2024. In 2024, the drug for stroke prevention Xarelto was
Xarelto patent expiration Xarelto holds a total of eight patents, with the last one expiring on J. The active drug patents protect the composition and utility of Rivaroxaban. Below is the detailed patent information:
Blockbuster patent to expire in 2024 - Xarelto (rivaroxaban) Xarelto (rivaroxaban) is a blood thinner that treats and helps prevent blood
Patents related to these products are in force and the latest projected U.S. expiration date is 2024 due to patent term extension and adjustment. XARELTO (
6. Xarelto. Company: Bayer / J J. Key patent expiration: 2024. Patented in 2024 and approved for medical use in the United States in 2024, Xarelto (Rivaroxaban) is used to treat and prevent blood clots.
Patents Listed in the FDA Orange Book Drug Database of Xarelto with information and expiry/expiration dates
Comments